The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT07206056




Registration number
Help: Registration number
NCT07206056
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
17/09/2025
Date registered
Help: Date registered
3/10/2025
Date last updated
Help: Date last updated
9/10/2026

Titles & IDs
Public title
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Scientific title
TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Additional trial identifiers [1] 0 0
2025-521880-10-00
Additional trial identifiers [2] 0 0
CDZR123A12107
Universal Trial Number (UTN)
Trial acronym
TulmiSTAR-01
Related trial records

Health condition
Health condition(s) studied:
Progressive Metastatic Castrate Resistant Prostate Cancer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Tulmimetostat DL1 QD
Treatment: Drugs - Tulmimetostat DL2 QD
Treatment: Drugs - Tulmimetostat DL3 QD
Treatment: Drugs - Tulmimetostat Doses 1 or 2 QD
Treatment: Drugs - Tulmimetostat RP2D QD
Treatment: Drugs - JSB462 Dose 1 QD
Treatment: Drugs - JSB462 Dose 2 QD
Treatment: Drugs - JSB462 QD
Treatment: Drugs - Standard of Care (SoC)

Experimental: Part 1a: Cohort DL1A - Tulmimetostat DL1 QD + JSB462 Dose 1 QD

Experimental: Part 1a: Cohort DL1B - Tulmimetostat DL1 QD + JSB462 Dose 2 QD

Experimental: Part 1a: Cohort DL2A - Tulmimetostat DL2 QD + JSB462 Dose 1 QD

Experimental: Part 1a: Cohort DL2B - Tulmimetostat DL2 QD + JSB462 Dose 2 QD

Experimental: Part 1a: Cohort DL3A - Tulmimetostat DL3 QD + JSB462 Dose 1 QD

Experimental: Part 1a: Cohort DL3B - Tulmimetostat DL3 QD + JSB462 Dose 2 QD

Experimental: Part 1b : Arm A - Tulmimetostat Dose 1 QD + JSB462 QD

Experimental: Part 1b: Arm B - Tulmimetostat Dose 2 QD + JSB462 QD

Experimental: Part 2: Arm 1 - Tulmimetostat RP2D QD + JSB462 QD

Active comparator: Part 2: Arm 2 - Standard of Care at the discretion of the investigator


Treatment: Drugs: Tulmimetostat DL1 QD
Part 1a (dose escalation):

Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

Treatment: Drugs: Tulmimetostat DL2 QD
Part 1a (dose escalation):

Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

Treatment: Drugs: Tulmimetostat DL3 QD
Part 1a (dose escalation):

Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

Treatment: Drugs: Tulmimetostat Doses 1 or 2 QD
Part 1b (dose expansion and optimization):

tulmimetostat doses 1 or 2 QD

Treatment: Drugs: Tulmimetostat RP2D QD
Part 2:

tulmimetostat Recommended Phase 2 Dose (RP2D) QD

Treatment: Drugs: JSB462 Dose 1 QD
JSB462 Dose 1 QD

Treatment: Drugs: JSB462 Dose 2 QD
JSB462 Dose 2 QD

Treatment: Drugs: JSB462 QD
The dose of JSB462 QD will be determined based on the totality of data from Part 1a

Treatment: Drugs: Standard of Care (SoC)
Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Part 1a: Dose-limiting toxicities (DLTs)
Timepoint [1] 0 0
Up to 28 days
Primary outcome [2] 0 0
Part 1a and Part 1b: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [2] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Primary outcome [3] 0 0
Part 1a and Part 1b: Number of Participants with dose adjustments
Timepoint [3] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Primary outcome [4] 0 0
Part 1a and Part 1b: Dose Intensity
Timepoint [4] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Primary outcome [5] 0 0
Part 1a and Part 1b: Duration of exposure to each study drug
Timepoint [5] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Primary outcome [6] 0 0
Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at Month 6
Timepoint [6] 0 0
Month 6
Secondary outcome [1] 0 0
Part 1a and Part 1b: Plasma concentrations of tulmimetostat and JSB462
Timepoint [1] 0 0
Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Secondary outcome [2] 0 0
Part 2: Plasma concentrations of tulmimetostat and JSB462
Timepoint [2] 0 0
Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Secondary outcome [3] 0 0
Part 1a and Part 1b: AUC of tulmimetostat and JSB462
Timepoint [3] 0 0
Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Secondary outcome [4] 0 0
Part 2: AUC of tulmimetostat and JSB462
Timepoint [4] 0 0
Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Secondary outcome [5] 0 0
Part 1a and Part 1b: Cmax of tulmimetostat and JSB462
Timepoint [5] 0 0
Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Secondary outcome [6] 0 0
Part 2: Cmax of tulmimetostat and JSB462
Timepoint [6] 0 0
Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Secondary outcome [7] 0 0
Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at 3, 9, and 12 months
Timepoint [7] 0 0
Month 3, Month 9, Month 12
Secondary outcome [8] 0 0
Part 1b and Part 2: radiographic progression free survival (rPFS)
Timepoint [8] 0 0
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 15 months
Secondary outcome [9] 0 0
Part 1b and Part 2: overall survival (OS)
Timepoint [9] 0 0
From date of randomization until date of death from any cause, assessed up to approximately 15 months
Secondary outcome [10] 0 0
Part 1b and Part 2: objective response (OR)
Timepoint [10] 0 0
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months
Secondary outcome [11] 0 0
Part 1b and Part 2: best overall response (BOR)
Timepoint [11] 0 0
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months
Secondary outcome [12] 0 0
Part 1b and Part 2: duration of response (DOR)
Timepoint [12] 0 0
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months
Secondary outcome [13] 0 0
Part 1b and Part 2: time to first symptomatic skeletal event (TTSSE)
Timepoint [13] 0 0
From randomization until the first occurrence of a new symptomatic bone fracture, spinal cord compression, tumor-related orthopedic surgery, radiation therapy for bone pain, or death, assessed up to 15 months.
Secondary outcome [14] 0 0
Part 2: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [14] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months
Secondary outcome [15] 0 0
Part 2: Number of Participants with dose adjustments
Timepoint [15] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months
Secondary outcome [16] 0 0
Part 2: Dose Intensity
Timepoint [16] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months
Secondary outcome [17] 0 0
Part 2: Duration of exposure to each study drug
Timepoint [17] 0 0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months

Eligibility
Key inclusion criteria
Key

* Participant is an adult man = 18 years of age.
* Participant must have histologically and/or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell features (current or prior biopsy of the prostate and/or metastatic site).
* Participant must have = 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained = 28 days prior to start of treatment (Part 1a dose escalation) or randomization (Part 1b dose expansion and Part 2).
* Participant must have progressive mCRPC.
* Participant must have a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
* Prior ARPI therapy:

* Part 1a and 1b only: must have progressed on at least one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide).
* Part 2 only: must have progressed on one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide).
* Prior chemotherapy:

* Part 1a dose escalation only: may have received = 2 prior lines of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting.
* Part 1b dose expansion/optimization only: may have received up to one prior line of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting.
* Part 2 only: Participants must be taxane-naïve in mCRPC setting; prior chemotherapy permitted in HSPC setting only

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Healthy volunteers
No
Key exclusion criteria
* Previous treatment with any PRC2 inhibitor, including but not limited to EZH2 inhibitors, EZH2/1 inhibitors, or embryonic ectoderm development (EED) inhibitors.
* Previous treatment with a protein degrader compound that targets the AR.
* Known hypersensitivity or contraindication to any of the study treatment components or its excipients or to drugs of similar chemical classes.
* Treatment with any investigational agent within 28 days (or 5 half-lives, whichever is longer) prior to study entry.
* Previous treatment with radioligand therapy in the mCRPC setting, except in Part 1a where participants may have received RLT in mCRPC setting.
* Participants with evidence of mCRPC or biochemical recurrence / PSA only disease or asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy and with normal PSA for = 1 year prior to study entry.
* Participants with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purpose of maintaining neurologic integrity. Those with leptomeningeal disease are eligible if those areas have been treated, are stable, and no neurological impairment is present. For those with parenchymal CNS metastasis (or a history of CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain with MRI (preferred) or CT with contrast.

Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - St Leonards
Recruitment hospital [2] 0 0
Novartis Investigative Site - Melbourne
Recruitment hospital [3] 0 0
Novartis Investigative Site - Liverpool
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
3000 - Melbourne
Recruitment postcode(s) [3] 0 0
2170 - Liverpool
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Washington
Country [9] 0 0
Canada
State/province [9] 0 0
Nova Scotia
Country [10] 0 0
China
State/province [10] 0 0
Beijing
Country [11] 0 0
Denmark
State/province [11] 0 0
Herlev
Country [12] 0 0
Denmark
State/province [12] 0 0
Odense C
Country [13] 0 0
Denmark
State/province [13] 0 0
Vejle
Country [14] 0 0
France
State/province [14] 0 0
Bordeaux
Country [15] 0 0
France
State/province [15] 0 0
Paris
Country [16] 0 0
Germany
State/province [16] 0 0
North Rhine-Westphalia
Country [17] 0 0
Germany
State/province [17] 0 0
Thuringia
Country [18] 0 0
Italy
State/province [18] 0 0
MI
Country [19] 0 0
Italy
State/province [19] 0 0
PD
Country [20] 0 0
Italy
State/province [20] 0 0
TO
Country [21] 0 0
Malaysia
State/province [21] 0 0
Sarawak
Country [22] 0 0
Mexico
State/province [22] 0 0
Mexico City
Country [23] 0 0
Poland
State/province [23] 0 0
Poznan
Country [24] 0 0
Singapore
State/province [24] 0 0
Singapore
Country [25] 0 0
Spain
State/province [25] 0 0
A Coruna
Country [26] 0 0
Spain
State/province [26] 0 0
Barcelona
Country [27] 0 0
Spain
State/province [27] 0 0
Madrid
Country [28] 0 0
United Kingdom
State/province [28] 0 0
Surrey
Country [29] 0 0
United Kingdom
State/province [29] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.